The tissue factor pathway inhibitor C536T mutation is not associated with the risk of stroke in young adults

Thrombosis and Haemostasis

Volumn 87, Issue 5, 2002, Pages 920-921

  Junker, Ralf ^a   Glahn, J ^a   Tidow, N ^a   Brinkmann, T ^a   Nabavi, D G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DISEASE CARRIER; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; SEQUENCE ANALYSIS; STROKE; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0036257537     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613109     Document Type: Letter

References (7)

1. A first mutation in the human tissue factor pathway inhibitor gene encoding (P151L) TFPI
2. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis
3. Prevalence of the C536T mutation in the tissue factor pathway inhibitor (TFPI) gene among patients with venous thromboembolic disease
4. The C536T transition in the tissue factor pathway inhibitor (TFPI) gene does not contribute to risk of venous thrombosis among carriers of factor V Leiden
5. The C536T transition in the tissue factor pathway inhibitor gene is not a common cause of venous thromboembolic disease in the UK population
6. The TFPI 536C→T mutation is not associated with increased risk for venous or arterial thrombosis
7. Experience from a multicentre stroke register: A preliminary report